Diamond Equity Comments on MAIA Biotechnology Q1 Earnings

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) – Stock analysts at Diamond Equity issued their Q1 2026 EPS estimates for shares of MAIA Biotechnology in a report issued on Tuesday, March 25th. Diamond Equity analyst H. Diamond anticipates that the company will post earnings per share of ($0.18) for the quarter. The consensus estimate for MAIA Biotechnology’s current full-year earnings is ($1.30) per share. Diamond Equity also issued estimates for MAIA Biotechnology’s Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.13) EPS and FY2026 earnings at ($0.69) EPS.

MAIA Biotechnology Price Performance

Shares of NYSEAMERICAN:MAIA opened at $1.65 on Wednesday. The stock has a market capitalization of $43.16 million, a P/E ratio of -1.20 and a beta of 0.20. MAIA Biotechnology has a 52-week low of $1.46 and a 52-week high of $5.99. The firm has a fifty day moving average of $1.86.

Hedge Funds Weigh In On MAIA Biotechnology

Several large investors have recently added to or reduced their stakes in MAIA. Geode Capital Management LLC boosted its holdings in shares of MAIA Biotechnology by 22.9% in the 3rd quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock valued at $541,000 after purchasing an additional 35,821 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of MAIA Biotechnology in the 4th quarter worth $77,000. Finally, XTX Topco Ltd acquired a new position in MAIA Biotechnology in the third quarter valued at $31,000. 5.65% of the stock is currently owned by hedge funds and other institutional investors.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.